Latest period
-$13.9M
YoY change
-31.5%
5Y CAGR
—
Peak year (FY2021)
$119M
Latest annual
-$38.3M
Operating Cash Flow history chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: -$38.3M
Operating Cash Flow growth chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: -31.5%
Operating Cash Flow history table for Ovid Therapeutics (OVID) from 2014 to 2025
| FY2025 | -$38.3M | -31.5% | +$17.6M | ||
| FY2024 | -$56M | +22.2% | -$10.2M | ||
| FY2023 | -$45.8M | -17.1% | +$9.45M | ||
| FY2022 | -$55.2M | -146.6% | -$174M | ||
| FY2021 | $119M | -329.9% | +$170M | ||
| FY2020 | -$51.6M | +1.0% | -$493K | ||
| FY2019 | -$51.1M | +12.1% | -$5.53M | ||
| FY2018 | -$45.6M | +44.8% | -$14.1M | ||
| FY2017 | -$31.5M | +76.8% | -$13.7M | ||
| FY2016 | -$17.8M | +224.5% | -$12.3M | ||
| FY2015 | -$5.49M | +1999.5% | -$5.22M | ||
| FY2014 | -$261K | — | — |
- FY2025-$38.3M-31.5%
- FY2024-$56M+22.2%
- FY2023-$45.8M-17.1%
- FY2022-$55.2M-146.6%
- FY2021$119M-329.9%
- FY2020-$51.6M+1.0%
- FY2019-$51.1M+12.1%
- FY2018-$45.6M+44.8%
- FY2017-$31.5M+76.8%
- FY2016-$17.8M+224.5%
- FY2015-$5.49M+1999.5%
- FY2014-$261K—
Operating Cash Flow values are taken from Ovid Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Ovid Therapeutics (OVID)
Operating Cash Flow for Ovid Therapeutics (OVID): headline value -$13.9M · YoY -31.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Ovid Therapeutics (OVID) operating cash flow totalled -$38.3M – plunged 31.5% year-over-year.
Ovid Therapeutics operating cash flow plunged from $119M in 2021 to -$38.3M in 2025, a 132.3% drawdown.
Across the available history, operating cash flow reached its high of $119M in 2021 and its low of -$56M in 2024.
Ovid Therapeutics Operating Cash Flow by Year
Ovid Therapeutics Operating Cash Flow 2025: -$38.3M
Ovid Therapeutics posted operating cash flow of -$38.3M in 2025, plunged 31.5% below 2024.
Ovid Therapeutics Operating Cash Flow 2024: -$56M
In 2024, Ovid Therapeutics reported operating cash flow of -$56M, grew 22.2% from 2023. This figure represents the lowest annual value in the available history.
Ovid Therapeutics Operating Cash Flow 2023: -$45.8M
Ovid Therapeutics operating cash flow in 2023 was -$45.8M, declined 17.1% below 2022.
Ovid Therapeutics Operating Cash Flow 2022: -$55.2M
2022's operating cash flow for Ovid Therapeutics came in at -$55.2M, plunged 146.6% below 2021.
Ovid Therapeutics Operating Cash Flow 2021: $119M
Ovid Therapeutics operating cash flow in 2021 was $119M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Operating Cash Flow
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest operating cash flow
| $24.5B | |
| $19.7B | |
| $19B | |
| $18.6B | |
| $16.8B | |
| $16.5B | |
| $9.96B | |
| $7.82B |
- $24.5B
- $19.7B
- $19B
- $18.6B
- $16.8B
- $16.5B
- $9.96B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.